China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant drop in short interest in March. As of March 13th, there was short interest totaling 31,586 shares, a drop of 39.9% from the February 26th total of 52,570 shares. Based on an average daily volume of 26,742 shares, the days-to-cover ratio is currently 1.2 days. Approximately 3.4% of the company’s shares are sold short.

China SXT Pharmaceuticals Price Performance

NASDAQ SXTC opened at $1.30 on Friday. China SXT Pharmaceuticals has a 12-month low of $1.27 and a 12-month high of $1,046.99. The company has a fifty day simple moving average of $4.24 and a 200 day simple moving average of $140.82.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) EPS for the quarter. The firm had revenue of $0.31 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, China SXT Pharmaceuticals has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals during the third quarter valued at approximately $78,000. Virtu Financial LLC raised its position in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in China SXT Pharmaceuticals in the 4th quarter valued at $36,000. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.